- Home
- ALT vs GBAB Comparison
ALT vs GBAB Comparison
Compare ALT & GBAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALT | GBAB |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.5M | 396.7M |
| IPO Year | 2005 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ALT | GBAB |
|---|---|---|
| Price | $2.91 | $13.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 73.0K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.56 | $13.51 |
| 52 Week High | $6.44 | $15.94 |
Technical Indicators
Market Signals| Indicator | ALT | GBAB |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 28.50 |
| Support Level | $2.87 | $13.51 |
| Resistance Level | $3.09 | $15.47 |
| Average True Range (ATR) | 0.17 | 0.15 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 30.36 | 1.57 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About GBAB Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust of Beneficial Interest
Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust is a diversified closed-end management investment company. Its investment objective is to provide current income with a secondary objective of long-term capital appreciation. Its products include Mutual funds, Unit investment trusts, Closed-end funds, Rydex funds, Credit income fund and others.